OSSTEC has raised $8 million to support the first-in-human U.S. procedures and planned commercial development of ASCENT, its 3D-printed cementless partial knee replacement system. The financing was led by EMBRYO Ventures, with participation from Neovate Capital, New Wave Ventures, Oxford Technology Innovation Finance, and Empirical Ventures.
OSSTEC plans to use the capital to advance its ASCENT implant and CLARITY instrumentation through the U.S. Food and Drug Administration clearance process and into first-in-human procedures.
The company expects the initial U.S. procedures to take place during the first half of 2027.
OSSTEC established U.S. operations earlier in 2026 and plans to use part of the financing to train and support surgeon faculty at leading partial knee replacement centers.
The company said approximately half of patients undergoing knee replacement may be candidates for a partial knee procedure, while only about 10% currently receive one.
Partial knee replacement preserves more of the patient’s natural bone and can provide faster recovery than total knee replacement.
OSSTEC is developing ASCENT around a cementless fixation approach intended to reduce the use of surgical cement and encourage biological fixation between the implant and bone.
The system is based on a 3D-printed biomimetic fixation platform developed from more than a decade of research involving implant fixation and osseointegration.
OSSTEC plans to use the same underlying platform to develop additional cementless joint replacement applications beyond partial knee procedures.
The company is also evaluating integration of its technology with robotic surgery platforms.
OSSTEC was founded in 2021 as a startup from Imperial College London and combines surgeon-led implant design with additive manufacturing.
ASCENT and CLARITY are not currently cleared by the FDA and are not available for sale in the United States.
KEY QUOTES:
“This financing moves our focus from preparation to patients. Surgeons tell us they would offer a partial knee to more patients if they could use next-generation cementless technology. ASCENT is designed to give them that, integrated with a familiar, streamlined surgical workflow, and the platform behind it is built to go further, with a pipeline of cementless applications beyond the knee.”
Max Munford, PhD, Founder And CEO Of OSSTEC
“We are excited to lead this financing round in OSSTEC, representing an exceptional opportunity to advance partial knee replacement. With its next-generation implant technology approaching first clinical use, we look forward to supporting the company in its ambition to improve patient outcomes and drive greater operational efficiency.”
Dr. Arash Moavenian, Chief Executive Of EMBRYO Ventures
